Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions

  10 June 2019

A recent analysis of antibiotics approved between 1999 and 2014, conducted by researchers at the Norwegian Institute of Public Health; the University of Oslo; the Center for Disease Dynamics, Economics & Policy (CDDEP); and Boston University, showed a lack of novelty and diversity regarding target pathogens and indications and a failure to address the most urgent resistance threats, including resistant Gram-negative bacteria. A global research and development strategy should incentivize development of broad-spectrum antibiotics for critically ill patients, as well as therapeutic alternatives to antibiotics, decreasing our dependence on traditional, small-molecule antibiotics.

Healthy patients   Smart innovation  
Back


Emerging Antimicrobials and Diagnostics in AMR 2019

International Matchmaking Symposium on 20 November, 2019 in Amsterdam, The Netherlands.

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!